Replies to post #40857 on Ariad Pharmaceuticals Inc fka ARIA

[zipjet]

I provided a link to the poster.

It is all right there.

Not sure the time of release. I posted it as soon as I found it.

After that the stock rallied.

[DewDiligence]

A predicted 40 percent decrease in SAEs with a 15 mg. reduction in dose while maintaining efficacy is fantastic news if true.

ARIA’s poster did not include the phrase, while maintaining efficacy in the statement you referenced; you added that. Moreover, the statement in question pertains to arterial thrombotic SAEs, not SAEs in general.

[jochenVt]

Not so positive as you are about this poster.
Yes, it says 40% reduction, but also that (only) 75% maintained MMR and 90% CCyR. I am not totally sure how this compares to the population that stayed on initial doses, but since they mention MCyR in the headline and then add these numbers later, I assume they are somewhat lower than the total population.
Now we know that these are heavily pretreated patients and responses are easier to achieve in earlier patient population, we just probably will not get these patients (at least not outside of t315i).
So I guess dose reduction will not come for free (or very cheap) in terms of effectiveness and we need to see what dose is the sweet (or least bitter) spot.